In an Israeli national cohort of patients with IBD (epi-IIRN), data were retrieved from 3737 patients with IBD and T2DM, of whom 633 were treated with GLP-1 RAs for a median follow-up of 6 years per patient. The gene discussed is GLP1R; the disease is inflammatory bowel disease.